You are here: Industry Insights > NeoImmuneTech

News List

NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy americanpharmaceuticalreview
May 28, 2021
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the first patient has been dosed in the pilot study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in progressive multifocal ...
NeoImmuneTech doses first patient in Covid-19 trial pharmaceutical-business-review
December 02, 2020
NeoImmuneTech has dosed the first patient in its phase 1 study designed to assess NT-I7 (efineptakin alfa) in adult patients with mild Covid-19.
NeoImmuneTech gets IND clearance for NT-I7 trial in locally recurrent SCCHN pharmaceutical-business-review
July 29, 2020
NeoImmuneTech announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent ...
NeoImmuneTech receives FDA orphan drug designation for NT-I7 to treat Progressive Multifocal Leukoencephalopathy pharmaceutical-business-review
June 17, 2020
NeoImmuneTech, a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NeoImmuneTech’s NT-I7 (efineptakin alfa) ...